Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025

Rhea-AI Summary

Corvus Pharmaceuticals (NASDAQ: CRVS) will provide a business update and report third quarter 2025 financial results on November 4, 2025. The company will host a conference call and live webcast at 4:30 pm ET / 1:30 pm PT. Participants can dial 1-800-717-1738 (toll-free U.S.) or 1-646-307-1865 (international), or join via the instant telephone access link and the company’s investor relations webcast page. A replay of the webcast will be available on the Corvus website for 90 days.

News Market Reaction – CRVS

+1.19%

2 alerts

+1.19% News Effect

+5.5% Peak Tracked

+$7M Valuation Impact

$585.68M Market Cap

0.6x Rel. Volume

On the day this news was published, CRVS gained 1.19%, reflecting a mild positive market reaction. Argus tracked a peak move of +5.5% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $7M to the company's valuation, bringing the market cap to $585.68M at that time.

Data tracked by StockTitan Argus on the day of publication.

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT

SOUTH SAN FRANCISCO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on November 4, 2025 at 4:30 pm ET (1:30 pm PT) to provide a business update and report third quarter 2025 financial results.  

The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website.  A replay of the webcast will be available on Corvus’ website for 90 days. 

About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com or follow the Company on LinkedIn.

INVESTOR CONTACT: 
Leiv Lea 
Chief Financial Officer 
Corvus Pharmaceuticals, Inc. 
+1-650-900-4522 
llea@corvuspharma.com   

MEDIA CONTACT: 
Sheryl Seapy 
Real Chemistry 
+1-949-903-4750 
sseapy@realchemistry.com   

FAQ

When will Corvus (CRVS) report third quarter 2025 results?

Corvus will report Q3 2025 results on November 4, 2025 during a 4:30 pm ET / 1:30 pm PT call and webcast.

How can investors join the Corvus (CRVS) November 4, 2025 conference call?

Dial 1-800-717-1738 (U.S.) or 1-646-307-1865 (international) or use the instant telephone access link provided by the company.

Where can I watch the Corvus (CRVS) live webcast for the Q3 2025 update?

The live webcast will be available via the investor relations section of the Corvus website.

Will there be a replay of the Corvus (CRVS) November 4, 2025 webcast?

Yes. A replay will be posted on Corvus’ website and will remain available for 90 days.

What time is the Corvus (CRVS) call for international participants on November 4, 2025?

The call begins at 4:30 pm ET / 1:30 pm PT; international participants can use the 1-646-307-1865 dial-in number or the webcast.